Healthcare provider profile · identity verified

William L. Guy, PH.D., M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · SOUTHFIELD, MI · NPI 1295748101

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show William L. Guy, PH.D., M.D. received $169,193.76 in general payments during 2025 across 206 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 71.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 9 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Fanapt, Rexulti.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.

Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fanapt by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$169,193.76

206 reported records · 7 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$121,153.55	71.6%	154	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$18,968.13	11.2%	12	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$14,910.47	8.8%	18	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$8,003.84	4.7%	14	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$6,106.28	3.6%	6	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$28.33	0.0%	1	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$23.16	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$129,013.00	41
Travel and Lodging	$20,370.80	96
Honoraria	$11,800.00	5
Consulting Fee	$4,080.00	2
Food and Beverage	$3,922.45	61
Education	$7.51	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$121,153.55	154	2025
Source payment records 2025-02-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-02-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-02-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.76 · Open Payments source 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $98.80 · Open Payments source 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,040.00 · Open Payments source 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $272.79 · Open Payments source 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $113.62 · Open Payments source 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $288.79 · Open Payments source 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.47 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $97.69 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,360.00 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $272.79 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $113.62 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.91 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,940.00 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $272.79 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $113.62 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,620.00 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $352.99 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $63.09 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $163.77 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.03 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $90.16 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $352.99 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $63.09 · Open Payments source 2025-03-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-03-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $352.99 · Open Payments source 2025-03-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $63.09 · Open Payments source 2025-03-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-03-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.80 · Open Payments source 2025-03-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.74 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $77.22 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-03-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $39.20 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.60 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,620.00 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $312.32 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $54.44 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $63.11 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.89 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,100.00 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $312.32 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $54.44 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $60.46 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.17 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $312.32 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $54.44 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $121.56 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $656.36 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.30 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $936.39 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $192.95 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $154.77 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.98 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $116.39 · Open Payments source 2025-06-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.24 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $36.40 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $69.00 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $108.20 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.95 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.05 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.80 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $117.78 · Open Payments source 2025-06-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $110.67 · Open Payments source 2025-06-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $189.28 · Open Payments source 2025-06-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,217.94 · Open Payments source 2025-06-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,211.10 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.17 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,840.00 · Open Payments source 2025-06-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $86.42 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,280.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.20 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.03 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $64.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.83 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $36.40 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.80 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $57.40 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $118.17 · Open Payments source 2025-07-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-07-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.74 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.90 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $109.38 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $846.97 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $195.20 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $93.80 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,200.00 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.42 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $996.97 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.20 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $64.00 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.28 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.60 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $39.20 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.91 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.90 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.16 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.93 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.00 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $58.97 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $39.20 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $115.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $228.97 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.09 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.80 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $992.44 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $68.47 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $405.48 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $623.68 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $92.33 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.60 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $39.80 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $64.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,840.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $35.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.97 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $37.88 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $198.10 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.72 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $73.13 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,840.00 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $118.90 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $612.84 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,087.55 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $121.78 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.10 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.68 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $128.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.90 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $69.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $39.20 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$18,968.13	12	2025
Source payment records 2025-01-29 · Teva Pharmaceuticals USA, Inc. · $9.80 · Open Payments source 2025-01-29 · Teva Pharmaceuticals USA, Inc. · $107.10 · Open Payments source 2025-01-29 · Teva Pharmaceuticals USA, Inc. · $2,996.00 · Open Payments source 2025-04-07 · Teva Pharmaceuticals USA, Inc. · $6,081.00 · Open Payments source 2025-08-14 · Teva Pharmaceuticals USA, Inc. · $23.88 · Open Payments source 2025-08-29 · Teva Pharmaceuticals USA, Inc. · $560.00 · Open Payments source 2025-09-10 · Teva Pharmaceuticals USA, Inc. · $124.99 · Open Payments source 2025-09-10 · Teva Pharmaceuticals USA, Inc. · $2,995.00 · Open Payments source 2025-10-09 · Teva Pharmaceuticals USA, Inc. · $14.56 · Open Payments source 2025-10-09 · Teva Pharmaceuticals USA, Inc. · $2,995.00 · Open Payments source 2025-11-13 · Teva Pharmaceuticals USA, Inc. · $65.80 · Open Payments source 2025-11-13 · Teva Pharmaceuticals USA, Inc. · $2,995.00 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$14,910.47	18	2025
Source payment records 2025-01-14 · Axsome Therapeutics, Inc. · $2,250.00 · Open Payments source 2025-01-14 · Axsome Therapeutics, Inc. · $107.30 · Open Payments source 2025-01-14 · Axsome Therapeutics, Inc. · $9.80 · Open Payments source 2025-01-15 · Axsome Therapeutics, Inc. · $3,250.00 · Open Payments source 2025-01-15 · Axsome Therapeutics, Inc. · $86.13 · Open Payments source 2025-01-15 · Axsome Therapeutics, Inc. · $132.30 · Open Payments source 2025-02-13 · Axsome Therapeutics, Inc. · $3,250.00 · Open Payments source 2025-02-13 · Axsome Therapeutics, Inc. · $124.94 · Open Payments source 2025-02-13 · Axsome Therapeutics, Inc. · $846.28 · Open Payments source 2025-02-13 · Axsome Therapeutics, Inc. · $749.15 · Open Payments source 2025-02-14 · Axsome Therapeutics, Inc. · $2,500.00 · Open Payments source 2025-02-14 · Axsome Therapeutics, Inc. · $4.74 · Open Payments source 2025-02-14 · Axsome Therapeutics, Inc. · $13.95 · Open Payments source 2025-02-14 · Axsome Therapeutics, Inc. · $143.49 · Open Payments source 2025-02-14 · Axsome Therapeutics, Inc. · $64.00 · Open Payments source 2025-02-14 · Axsome Therapeutics, Inc. · $789.19 · Open Payments source 2025-02-14 · Axsome Therapeutics, Inc. · $39.20 · Open Payments source 2025-04-04 · Axsome Therapeutics, Inc. · $550.00 · Open Payments source
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$7,996.33	13	2025
Source payment records 2025-01-28 · Otsuka America Pharmaceutical, Inc. · $11.71 · Open Payments source 2025-01-29 · Otsuka America Pharmaceutical, Inc. · $20.35 · Open Payments source 2025-03-18 · Otsuka America Pharmaceutical, Inc. · $12.37 · Open Payments source 2025-04-18 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-14 · Otsuka America Pharmaceutical, Inc. · $18.10 · Open Payments source 2025-05-21 · Otsuka America Pharmaceutical, Inc. · $2,548.00 · Open Payments source 2025-05-21 · Otsuka America Pharmaceutical, Inc. · $12.60 · Open Payments source 2025-07-29 · Otsuka America Pharmaceutical, Inc. · $16.57 · Open Payments source 2025-09-30 · Otsuka America Pharmaceutical, Inc. · $13.38 · Open Payments source 2025-10-13 · Otsuka America Pharmaceutical, Inc. · $123.63 · Open Payments source 2025-10-13 · Otsuka America Pharmaceutical, Inc. · $546.97 · Open Payments source 2025-10-17 · Otsuka America Pharmaceutical, Inc. · $4,312.00 · Open Payments source 2025-10-28 · Otsuka America Pharmaceutical, Inc. · $9.65 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$6,106.28	6	2025
Source payment records 2025-09-09 · Vanda Pharmaceuticals Inc. · $2,310.00 · Open Payments source 2025-11-03 · Vanda Pharmaceuticals Inc. · $18.90 · Open Payments source 2025-11-03 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-11-13 · Vanda Pharmaceuticals Inc. · $124.98 · Open Payments source 2025-11-13 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-11-13 · Vanda Pharmaceuticals Inc. · $22.40 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$28.33	1	2025
Source payment records 2025-03-12 · Alkermes, Inc. · $28.33 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$28.33	1	2025
Source payment records 2025-03-12 · Alkermes, Inc. · $28.33 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$23.16	1	2025
Source payment records 2025-09-02 · E.R. Squibb & Sons, L.L.C. · $23.16 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$7.51	1	2025
Source payment records 2025-08-12 · Otsuka America Pharmaceutical, Inc. · $7.51 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FANAPT fanapt	2025	Fanapt	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference	2025	FANAPT open payments reported associated product	CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535	Fanapt · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Quetiapine Fumarate	Quetiapine Fumarate	120	25
Gabapentin	Gabapentin	94	24
Bupropion Xl	Bupropion Hcl	73	11
Lamotrigine	Lamotrigine	57	12
Alprazolam	Alprazolam	56	14
Clonazepam	Clonazepam	54	suppressed
Trazodone Hcl	Trazodone Hcl	48	14
Duloxetine Hcl	Duloxetine Hcl	45	11
Vilazodone Hcl	Vilazodone Hcl	45	suppressed
Lurasidone Hcl	Lurasidone Hcl	44	suppressed
Pregabalin	Pregabalin	44	12
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	43	suppressed
Sertraline Hcl	Sertraline Hcl	35	suppressed
Eszopiclone	Eszopiclone	33	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	33	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	31	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Bupropion Hcl Sr	Bupropion Hcl	26	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	26	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	26	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	23	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	22	suppressed
Olanzapine	Olanzapine	21	suppressed
Methylphenidate Er	Methylphenidate Hcl	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Divalproex Sodium Er	Divalproex Sodium	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Aripiprazole	Aripiprazole	16	suppressed
Benztropine Mesylate	Benztropine Mesylate	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Rexulti	Brexpiprazole	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Fanapt	Iloperidone	12	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	12	suppressed
Paliperidone Er	Paliperidone	12	suppressed
Concerta	Methylphenidate Hcl	11	suppressed
Prazosin Hcl	Prazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$169,193.76 · 206 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, LYBALVI, REXULTI	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Fanapt play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error